Reference is made to the extraordinary general meeting in Lifecare ASA (the “Company”) held on 17 September 2024, where it was resolved to carry out a share consolidation (reverse split) in the ratio of 13:1.
The share consolidation has now been registered with the Norwegian Register of Business Enterprises, and the Company’s share capital is NOK 78,112,907.60 (unchanged) divided on 15,021,713 shares, each with a nominal value of NOK 5.20.
About Lifecare:
Lifecare is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.